The 2026 Access to Medicine Index, released on November 10, found that 69% of late-stage drug candidates now have access plans, more than three times the proportion recorded in 2018. This shift towards incorporating access considerations earlier in drug development is a positive trend, according to Claudia Martínez, the Access to Medicine Foundation's director of research. The index assesses whether drugmakers address barriers to availability, affordability, and reliable supply before products reach the market.
Despite this progress, having an access plan does not necessarily mean medicines will reach poorer patients. Among non-communicable disease projects with access plans, 43% focus only on regulatory registration, largely directed at upper-middle-income countries, with limited coverage of low-income and lower-middle-income markets. Non-communicable diseases, such as diabetes, cancer, and cardiovascular disease, account for 73% of deaths in low- and middle-income countries, yet receive relatively little global health funding.
Partnerships with non-commercial organisations appear to improve access planning, with 95% of late-stage drug development projects involving access-oriented partners having access plans. Examples include Pfizer's group B streptococcus vaccine, developed with the Gates Foundation, and a once-monthly HIV prevention pill being developed by MSD. However, access plans were more likely to address availability than affordability and reliable supply.
Cancer research is a significant area of focus, with cancer accounting for almost half of all clinical drug candidates in the research pipeline and 40% of marketed products assessed by the index. Access planning in oncology has improved, with 65% of pipeline candidates now covered by access plans, compared with 5% in 2018. The index found access strategies for 74% of assessed cancer products in lower-middle-income countries, but only 19% in low-income countries.
Companies such as AstraZeneca, Bristol Myers Squibb (BMS), and Roche are highlighted for initiatives extending beyond medicine supply to include diagnostic services, health-worker training, and patient support. Roche's access plans cover an average of 12 countries, more than twice the industry average. The company is conducting cancer trials in Kenya and Uganda, countries in a region historically underrepresented in oncology research.
In Uganda, BMS is expanding access to immunotherapy at the Uganda Cancer Institute, including publicly financed treatment with nivolumab. The company is also supporting access in Zambia through a public-private partnership at the Cancer Diseases Hospital. Martínez said partnerships involving hospitals, governments, and clinics were helping address barriers that have limited access to immunotherapy.
Despite the progress, access in low-income and lower-middle-income countries remains heavily dependent on targeted programmes, which can limit the scale and consistency of treatment. The foundation urged pharmaceutical companies to involve governments, local researchers, and healthcare practitioners earlier in drug development and work with partners in low- and middle-income countries to design access strategies.
Key points
- Pharmaceutical companies are increasingly planning to make new medicines available in low- and middle-income countries before regulatory approval.
- Access to medicines remains uneven, particularly for non-communicable diseases.
- Partnerships with non-commercial organisations can improve access planning.
Reporting sources
- Drugmakers advance access plans, but gaps remain · The Independent magazine